{
  "id": "5e4b56276d0a27794100001d",
  "type": "summary",
  "question": "Describe the mechanism of action of Trilaciclib.",
  "ideal_answer": "Trilaciclib is cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, which act by inhibiting progression from the G1 to S phases of the cell cycle.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31504118",
    "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
    "http://www.ncbi.nlm.nih.gov/pubmed/28446688"
  ],
  "snippets": [
    {
      "text": "Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that the coadministration of G1T28 (trilaciclib), which is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), contemporaneously with cytotoxic chemotherapy protects murine hematopoietic stem cells (HSCs) from chemotherapy-induced exhaustion in a serial 5-fluorouracil treatment model. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28446688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that the coadministration of G1T28 (trilaciclib), which is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), contemporaneously with cytotoxic chemotherapy protects murine hematopoietic stem cells (HSCs) from chemotherapy-induced exhaustion in a serial 5-fluorouracil treatment model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28446688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that the coadministration of G1T28 ( trilaciclib) , which is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 ( CDK4/6) , contemporaneously with cytotoxic chemotherapy protects murine hematopoietic stem cells ( HSCs ) from chemotherapy-induced exhaustion in a serial 5-fluorouracil treatment model",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28446688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy ( myelopreservation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504118",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504118",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504118",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31504118",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}